💡Back to School is BioCentury's annual forward-looking analysis that assesses a broad issue critical to the biopharma industry, from reimagining FDA to redefining how targets are chosen to building the next generation of sustainable biotechs.
The 34th installment of the Back to School series digs into the challenges of expediting first-in-human trials and examines the global initiatives to reform countries' clinical enterprises and enable innovators' success in the earliest stages of clinical development.
Create custom folders to save relevant and important content. Access and manage your saved searches and alerts.
Turn any search into a custom feed, to easily keep up on the most recent BioCentury analysis, conveniently organized by the topics of your choice.
View the latest Editors' Picks. Easily access BioCentury's Daily and Weekly Editions.